Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health

Abdominal Obesity Clinical Trial

— Neurocan  

Official title:

Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health in Individuals With Abdominal Obesity: a Double-blind Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05062954
• Other study ID #: 128976
• Status: Recruiting
• Phase: N/A
• Start date: October 21, 2021
• Est. completion date: August 2023

Study information

• Verified date: September 2022
• Source: Laval University
• Contact: Andréanne Michaud, PhD
• Phone: 418-656-8711
• Email: Andreanne.Michaud[@]fsaa.ulaval.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this double-blind, parallel, randomized placebo-controlled clinical trial is to evaluate the effects of consumption of polyphenol-rich cranberry extract standardized in PACs (36 mg PACs/capsule) on cardiometabolic and neurocognitive health in women and men presenting abdominal obesity over an 8-week intervention period.

The study will be conducted at Quebec Heart and Lung Institute - Laval University. The study will involve a total of 60 adult men and women presenting abdominal obesity. Included participants will be randomly assigned to the consumption of a cranberry extract or a placebo at a rate of one capsule per day for 8 weeks (56 days). The main outcomes are changes in metabolic profile, neurocognitive performance as well as brain structure and function following polyphenol-rich cranberry extract standardized in PACs compared with the placebo.

Description:

Background :

Abdominal obesity is associated with impaired cognitive function and increased risk of neurodegenerative diseases. The metabolic disorders associated with obesity may lead to alterations in brain function and structure, explaining the link between obesity and some cognitive dysfunction. Magnetic resonance imaging (MRI) studies show that obese individuals are characterized by gray matter atrophy in brain regions involved in self-control. Atrophy and alteration of white matter fibers have also been observed in these individuals. However, the mechanisms explaining these changes are not yet elucidated. It has been suggested that metabolic and inflammatory alterations associated with abdominal obesity may lead to these brain alterations.

It is well known that dietary intake influences the composition and diversity of the gut microbiota and that its disruption plays a central role in the development of obesity, chronic low-grade inflammation, insulin resistance and cardiovascular disease. Some studies have reported improvements in blood pressure, lipid profile, glucose homeostasis, endothelial function, arterial stiffness and inflammation following cranberry consumption, but others found no significant changes. A recent meta-analysis reported that taking a polyphenol-rich supplement is associated with improved cognitive function in young adults. Although the mechanisms underlying the beneficial effects of polyphenols on brain function and cognition remain to be elucidated, some studies suggest that these effects may be associated with their anti-inflammatory and antioxidant properties and their possible effect on the cerebrovascular system. To our knowledge, there are no randomized controlled studies that have evaluated the effects of polyphenol-rich cranberry extract standardized in PACs on neurometabolic and neurocognitive functions in participants with abdominal obesity.

Objectives and Hypothesis:

The objective of this double-blind, randomized placebo-controlled clinical trial is to evaluate the effects of consumption of polyphenol-rich cranberry extract standardized in PACs (36 mg PACs/capsule) on cardiometabolic and neurocognitive health in abdominally obese women and men over an 8-week period.

The overall hypothesis is that standardized extract of PACs from cranberry improves the metabolic profiles in abdominally obese individuals and this will have a beneficial impact on brain and neurocognitive functions.

Methodology:

Sixty men and women with a BMI equal or greater than 25 kg/m2 and an altered blood lipid profile (triglycerides) will be recruited at the IUCPQ-Université Laval via social networks and Laval University's recall lists. The study will include 3 visits to the IUCPQ-Université Laval as well as the consumption of a cranberry extract or a placebo at a rate of one capsule per day for 8 weeks (56 days). The eligibility visit (V1) consists of completing a medical history questionnaire, and anthropometric and fasting blood lipid measurements. Individuals eligible to participate will then be invited to 2 identical visits at the IUCPQ-Université Laval (V2 and V3). At visit 2, cognitive tasks, anthropometric measurements, blood pressure, MRI (Philips 3T) and a pan-body DXA will be performed in all participants. Cognitive function will be measured using a battery of validated neurocognitive tasks. On the morning of each MRI session, fasting blood samples will be collected. Stool samples will be collected by participants prior to each visit 2 and 3 to measure microbiota composition. Following visit 2, participants will leave with capsules of cranberry extract containing 36 mg of PACS or a placebo (double-blind randomization) and will be asked to consume one capsule per day for 56 consecutive days. They will return for the 3rd visit (identical to V2) 8 weeks after starting the supplements. Dietary and physical activity questionnaires will also be completed online before visits 2 and 3. At the beginning of the visits, any changes in the participant's health condition and use of medications and natural health products will be documented. A follow-up phone call will be scheduled with each participant on day 28 of the intervention to ensure that the intervention is going well. Adverse events related to supplementation will be documented. An end-of-study questionnaire will be completed by the participant at the last visit (V3) to confirm study blinding. Participants will be asked to report the remaining capsules at the last visit (V3), which will allow assessment of compliance with the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion criteria:

• Men and women aged between 30-70 years old;

• BMI equal or greater than 25 kg/m2;

• Waist circumference =85 cm for women, =90 cm for men;

• Stable weight in the past 3 months;

• Plasma triglycerides levels =1.5 mmol/L for men and women;

• Access to a computer and Internet.

Exclusion criteria:

• Any severe uncontrolled medical, surgical, neurological or psychiatric condition;

• Medication for dyslipidemias, CVD, T2D or obesity;

• Medication that may affect the CNS;

• Gastro-intestinal conditions or disorders likely to impact on absorption;

• History of nephrolithiasis or urolithiasis;

• Contraindications to MRI (cardiac pacemaker/defibrillator, cochlear implant or other ear implant, implanted insulin pump or other infusion pump systems, neurostimulator or other electronic/magnetic implant or device, any type of prothesis, aneurysm clips, any metallic fragments, vascular access port, catheter, dental retainer, claustrophobia, surgery in the last 3 months);

• Anticoagulant/blood thinning medication in the last month;

• Pregnant or breastfeeding women;

• Substance or alcohol abuse;

• Known allergy or intolerance to cranberry;

• Currently smoking.

Related Conditions & MeSH terms

• Abdominal Obesity
• Obesity
• Obesity, Abdominal

Intervention

Dietary Supplement:
• Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins
Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
• Placebo supplement
Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.

Locations

Country	Name	City	State
Canada	Quebec Heart and Lung Institute - Laval University	Québec

Sponsors (1)

Lead Sponsor	Collaborator
Laval University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in basic plasma lipid-lipoprotein profile	Fasting blood samples	8 weeks
Primary	Changes in glucose homeostasis	Fasting blood samples	8 weeks
Primary	Changes in lipopolysaccharide binding protein (LBP)	Fasting blood samples	8 weeks
Primary	Changes in white matter health assessment	T2-weighted images, axial fluid-attenuated inversion recovery	8 weeks
Primary	Changes in brain density in key regions	Structural MRI measurements	8 weeks
Primary	Changes in functional brain connectivity	Resting state functional MRI	8 weeks
Primary	Changes in white matter integrity	Diffusion tensor imaging	8 weeks
Primary	Changes in cerebral vasculature	Magnetic resonance angiography time-of-flight (MRA-TOF)	8 weeks
Primary	Gut microbiota composition	Measures in fecal samples	8 weeks
Secondary	Changes in executive function	Stroop	8 weeks
Secondary	Changes in attention span and short-term working memory	Digit Span	8 weeks
Secondary	Changes in cognitive flexibility and speed of information processing	Trail Making Test (Parts A and B)	8 weeks
Secondary	Changes in biomarkers of gut endotoxemia	Blood plasma samples will be analysed for presence of lipopolysaccharide (LPS)	8 weeks
Secondary	Changes in biomarkers of gut permability	Blood plasma samples will be analysed for presence of zonulin	8 weeks
Secondary	Changes in body fat distribution	Abdominal axial T1-weighted slices	8 weeks